Erik P Sulman
Erik P Sulman
Professor and Vice-Chair of Radiation Oncology, NYU Langone Health
Подтвержден адрес электронной почты в домене - Главная страница
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma
H Noushmehr, DJ Weisenberger, K Diefes, HS Phillips, K Pujara, ...
Cancer cell 17 (5), 510-522, 2010
A randomized trial of bevacizumab for newly diagnosed glioblastoma
MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, ...
New England Journal of Medicine 370 (8), 699-708, 2014
The transcriptional network for mesenchymal transformation of brain tumours
MS Carro, WK Lim, MJ Alvarez, RJ Bollo, X Zhao, EY Snyder, EP Sulman, ...
Nature 463 (7279), 318-325, 2010
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma
KPL Bhat, V Balasubramaniyan, B Vaillant, R Ezhilarasan, K Hummelink, ...
Cancer cell 24 (3), 331-346, 2013
Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment
Q Wang, B Hu, X Hu, H Kim, M Squatrito, L Scarpace, AC deCarvalho, ...
Cancer cell 32 (1), 42-56. e6, 2017
m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program
S Zhang, BS Zhao, A Zhou, K Lin, S Zheng, Z Lu, Y Chen, EP Sulman, ...
Cancer cell 31 (4), 591-606. e6, 2017
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer
JW Welsh, R Komaki, A Amini, MF Munsell, W Unger, PK Allen, JY Chang, ...
Journal of Clinical Oncology 31 (7), 895, 2013
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
CE Pelloski, KV Ballman, AF Furth, L Zhang, E Lin, EP Sulman, K Bhat, ...
Journal of Clinical Oncology 25 (16), 2288-2294, 2007
A multigene predictor of outcome in glioblastoma
H Colman, L Zhang, EP Sulman, JM McDonald, NL Shooshtari, A Rivera, ...
Neuro-oncology 12 (1), 49-57, 2010
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
AL Rivera, CE Pelloski, MR Gilbert, H Colman, C De La Cruz, EP Sulman, ...
Neuro-oncology 12 (2), 116-121, 2010
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial
A Mahajan, S Ahmed, MF McAleer, JS Weinberg, J Li, P Brown, S Settle, ...
The lancet oncology 18 (8), 1040-1048, 2017
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
J Beiko, D Suki, KR Hess, BD Fox, V Cheung, M Cabral, N Shonka, ...
Neuro-oncology 16 (1), 81-91, 2014
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma
KPL Bhat, KL Salazar, V Balasubramaniyan, K Wani, L Heathcock, ...
Genes & development 25 (24), 2594-2609, 2011
A region of consistent deletion in neuroblastoma maps within human chromosome 1p36. 2-36.3
PS White, JM Maris, C Beltinger, E Sulman, HN Marshall, M Fujimori, ...
Proceedings of the National Academy of Sciences 92 (12), 5520-5524, 1995
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
A Olar, KM Wani, KD Alfaro-Munoz, LE Heathcock, HF van Thuijl, ...
Acta neuropathologica 129 (4), 585-596, 2015
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
K Gabrusiewicz, B Rodriguez, J Wei, Y Hashimoto, LM Healy, SN Maiti, ...
JCI insight 1 (2), 2016
IMRT reirradiation of head and neck cancer—disease control and morbidity outcomes
EP Sulman, DL Schwartz, TT Le, KK Ang, WH Morrison, DI Rosenthal, ...
International Journal of Radiation Oncology* Biology* Physics 73 (2), 399-409, 2009
TERT promoter mutations and risk of recurrence in meningioma
F Sahm, D Schrimpf, A Olar, C Koelsche, D Reuss, J Bissel, A Kratz, ...
JNCI: Journal of the National Cancer Institute 108 (5), 2016
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer …
JM Maris, MJ Weiss, C Guo, RB Gerbing, DO Stram, PS White, ...
Journal of clinical oncology 18 (9), 1888-1899, 2000
Significance of chromosome 1p loss of heterozygosity in neuroblastoma
JM Maris, PS White, CP Beltinger, EP Sulman, RP Castleberry, JJ Shuster, ...
Cancer research 55 (20), 4664-4669, 1995
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20